Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an – GlobeNewswire October 10, 2023
Dying of idiopathic pulmonary fibrosis, a disease I never knew existed September 6, 2022September 5, 2022
Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis: A Randomized Controlled Trial: Annals of Internal Medicine: Vol 0, No 0 November 30, 2021November 29, 2021